JP2023508165A5 - - Google Patents

Info

Publication number
JP2023508165A5
JP2023508165A5 JP2022538879A JP2022538879A JP2023508165A5 JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5 JP 2022538879 A JP2022538879 A JP 2022538879A JP 2022538879 A JP2022538879 A JP 2022538879A JP 2023508165 A5 JP2023508165 A5 JP 2023508165A5
Authority
JP
Japan
Prior art keywords
cancer
patient
expression
mdm2 antagonist
bap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508165A (ja
Filing date
Publication date
Priority claimed from GBGB1919219.4A external-priority patent/GB201919219D0/en
Application filed filed Critical
Publication of JP2023508165A publication Critical patent/JP2023508165A/ja
Publication of JP2023508165A5 publication Critical patent/JP2023508165A5/ja
Priority to JP2025122610A priority Critical patent/JP2025160292A/ja
Pending legal-status Critical Current

Links

JP2022538879A 2019-12-23 2020-12-23 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー Pending JP2023508165A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122610A JP2025160292A (ja) 2019-12-23 2025-07-22 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919219.4 2019-12-23
GBGB1919219.4A GB201919219D0 (en) 2019-12-23 2019-12-23 Cancer biomarkers
PCT/IB2020/062366 WO2021130682A2 (en) 2019-12-23 2020-12-23 Biomarkers for cancer therapy using mdm2 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122610A Division JP2025160292A (ja) 2019-12-23 2025-07-22 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー

Publications (2)

Publication Number Publication Date
JP2023508165A JP2023508165A (ja) 2023-03-01
JP2023508165A5 true JP2023508165A5 (cg-RX-API-DMAC7.html) 2024-01-09

Family

ID=69322948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538879A Pending JP2023508165A (ja) 2019-12-23 2020-12-23 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー
JP2025122610A Pending JP2025160292A (ja) 2019-12-23 2025-07-22 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122610A Pending JP2025160292A (ja) 2019-12-23 2025-07-22 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー

Country Status (14)

Country Link
US (1) US20230338337A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081801A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023508165A (cg-RX-API-DMAC7.html)
KR (1) KR20220119423A (cg-RX-API-DMAC7.html)
CN (1) CN115066614A (cg-RX-API-DMAC7.html)
AU (1) AU2020414482A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012444A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162624A1 (cg-RX-API-DMAC7.html)
GB (1) GB201919219D0 (cg-RX-API-DMAC7.html)
IL (1) IL293934A (cg-RX-API-DMAC7.html)
MX (1) MX2022007876A (cg-RX-API-DMAC7.html)
PH (1) PH12022551443A1 (cg-RX-API-DMAC7.html)
TW (1) TW202135803A (cg-RX-API-DMAC7.html)
WO (1) WO2021130682A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP2021505661A (ja) * 2017-11-30 2021-02-18 ジャズ ファーマシューティカルズ アイルランド リミテッド アスパラギナーゼを用いた治療法
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
EP4255488A1 (en) * 2020-12-01 2023-10-11 Nanobiotix Porous, high-z and carbon-free particles as radioenhancers
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
EP4380691A1 (en) * 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Methods for the treatment of cancer
JP2025508016A (ja) * 2022-03-04 2025-03-21 大鵬薬品工業株式会社 Iapアンタゴニスト化合物を用いたがんの治療方法及び併用療法
US20240217985A1 (en) * 2022-12-22 2024-07-04 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS
CN118272524A (zh) * 2022-12-30 2024-07-02 康方药业有限公司 Cd74的医药用途
WO2025235391A1 (en) * 2024-05-06 2025-11-13 University Of Massachusetts P53 protein stabieizers inceuding mdm2 inhibitors as a "chemicae mastectomy" strategy in breast cancer brca1/2 mutation carriers

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6307035B1 (en) * 1996-08-02 2001-10-23 The Wistar Institute Of Anatomy And Biology BRCA1 associated polynucleotide (BAP-1) and uses therefor
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US10344333B2 (en) 2011-02-18 2019-07-09 Institute For Cancer Research Methods for diagnosing a predisposition to develop cancer
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
RU2015133939A (ru) 2013-02-21 2017-03-27 Ф. Хоффманн-Ля Рош Аг Асимметрический синтез замещенного пирролидин-2-карбоксамида
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
RU2015154097A (ru) 2013-06-24 2017-07-26 Ф. Хоффманн-Ля Рош Аг Стабильный внутривенный препарат
AU2014286237B2 (en) * 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
TWI635089B (zh) 2013-09-04 2018-09-11 第一三共股份有限公司 螺氧基吲哚衍生物之製造方法
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
CN115368356B (zh) * 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
CN106795561B (zh) * 2014-06-19 2021-04-16 纪念斯隆-凯特琳癌症中心 用于对ezh2抑制剂的应答的生物标志物
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
US20190038633A1 (en) 2016-02-08 2019-02-07 Epizyme, Inc. Methods of treating cancer
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
GB201615842D0 (en) 2016-09-16 2016-11-02 Ucl Business Plc Cell death biomarker
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP7153775B2 (ja) Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測
Moneta et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features
US10626180B2 (en) Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP6038128B2 (ja) レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2337864B1 (en) Biomarkers for predicting the development of chronic autoimmune diseases
JP2024508895A5 (cg-RX-API-DMAC7.html)
CA2988673A1 (en) Epigenetic chromosome interactions
Higham et al. Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease
JP5706817B2 (ja) ループスのためのバイオマーカー
JP2023539867A5 (cg-RX-API-DMAC7.html)
JP2026002914A (ja) 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法
Pisani et al. Proteomic insights on the metabolism in inflammatory bowel disease
Bolko et al. Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis
de Montai et al. Interferon-α biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: a monocentric study of 184 patients
US20170145501A1 (en) Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3417291B1 (en) Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease
Mori et al. Contribution of HLA-DRB1* 04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis
EP2954325B1 (en) Diagnosis of rheumatoid arthritis
Koca et al. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease
Asgari et al. Antibodies against interferon-beta in neuromyelitis optica patients
CN104105967B (zh) 生腱蛋白c及其在类风湿关节炎的用途
Nishijima et al. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
US11779643B2 (en) Methods and compositions for the treatment of an inflammatory bowel disease
WO2019208542A1 (ja) スティル病と敗血症との鑑別用バイオマーカー
WO2018020060A1 (es) Método para predecir la respuesta clínica a un tratamiento con agentes antiinflamatorios